scholarly journals Endocrine Markers of Fertility Potential in Reproductive Age Women with Idiopathic Hyperprolactinemia

2020 ◽  
pp. 71-77
Author(s):  
Alina Valerievna Atalyan ◽  
Leonid Fedorovich Shelokhov ◽  
Lyubov Ilinichna Kolesnikova
Keyword(s):  
Ovarian Function ◽  
Premenopausal Women ◽  
Thyroid Stimulating Hormone ◽  
Reproductive Age ◽  
Free Triiodothyronine ◽  
Reproductive Ability ◽  
Study Results ◽  
Gynecological Disorder ◽  
Fertile Women ◽  
Stimulating Hormone

Background: Hyperprolactinemia (HP) is a common endocrine gynecological disorder in women of reproductive age manifested with menstrual irregularity and sterility subfertility among the majority of women with this disorder. Objective: The aim of this study was to assess the endocrinal markers of inferility in premenopausal women with idiopathic hyperprolactinemia. Materials and Metahodology: The study included 82 women: 27 healthy women, 22 fertile women with idiopathic HP and 33 patients with endocrine sub fertility with idiopathic HP.  All women underwent a standard history taking, clinical examinations.  Lab tests were performed in all women and included the detection of the concentrations of prolactin, thyroid-stimulating hormone, thyroxine, triiodothyronine, cortisol, gonadotrophic hormones, testosterone, and estradiol by ELISA method.   Results: The study results demonstrated that subfertile women with HP are characterized by an increase of follicle-stimulating hormone and free triiodothyronine and a decrease of estradiol and cortisol when compared with fertile patients with HP and Healthy patients. Conclusion: The better glucocorticoid and ovarian function of fertile women with HP supposed to be an essential issue in their reproductive ability.

scholarly journals Incidence and Interrelated Factors in Patients With Congenital Hypothyroidism as Detected by Newborn Screening in Guangxi, China

2015 ◽  
Vol 2 ◽  
pp. 2333794X1456719 ◽  
Author(s):  
Xin Fan ◽  
Shaoke Chen ◽  
Jiale Qian ◽  
Suren Sooranna ◽  
Jingi Luo ◽  
...  
Keyword(s):  
Newborn Screening ◽  
Congenital Hypothyroidism ◽  
Screening Program ◽  
Thyroid Stimulating Hormone ◽  
Who Guidelines ◽  
Newborn Screening Program ◽  
Study Results ◽  
Stimulating Hormone

Background. A newborn screening program (NSP) for congenital hypothyroidism (CH) was carried out in Guangxi in order to understand the incidence of CH and the factors interrelated to major types of CH in this region of China. Methods. During 2009 to 2013, data from 930 612 newborns attending NSP in Guangxi were collected. Patients were classified with either permanent CH (PCH) or transient CH (TCH) after 2 years of progressive study. Results. A total of 1210 patients were confirmed with CH with an incidence of 1/769, including 68 PCH and 126 TCH cases with incidences of 1/6673 and 1/3385, respectively. The frequency of thyroid stimulating hormone values greater than 5 mIU/L was 7.2%, which, based on WHO guidelines, suggests that the population was mildly iodine deficient. Conclusions. The incidence of CH was high in Guangxi. Approximately two thirds of CH patients were TCH, which may be due to a deficiency in iodine within the population.

Subclinical Hyperthyroidism: Diagnostic Criteria and Principles of Treatment

2016 ◽  
pp. 75-79
Author(s):  
Vita Galitskaya
Keyword(s):  
Hormone Receptors ◽  
Color Doppler ◽  
Specific Treatment ◽  
Nodular Goiter ◽  
Thyroid Stimulating Hormone ◽  
Free Thyroxine ◽  
Subclinical Hyperthyroidism ◽  
Mineral Density ◽  
Free Triiodothyronine ◽  
Stimulating Hormone

This article presents the European Thyroid Association guidelines for diagnosis and treatment of subclinical hyperthyroidism, 2015. Determination of thyroid1stimulating hormone levels can help to diagnose a variety of pathological conditions: hypertension, cardiac fibrillation, atrial fibrillation, mineral density reduction in bones, menstrual irregularities, infertility, which require specific treatment after detection of hormonal status disorders (subclinical, overt), taking into account the patient’s age. Diagnosis of endogenous subclinical hyperthyroidism is based solely on the results of laboratory tests, not clinical criteria. Endogenous subclinical hyperthyroidism is defined by the presence of sub-normal levels of thyroid-stimulating hormone with normal levels of free thyroxine, total triiodothyronine, and/or free triiodothyronine. There are two categories of endogenous subclinical hyperthyroidism: stage 1 – the level of thyroid-stimulating hormone is 0,1–0,39 mIU/l; stage 2 – the level of thyroid-stimulating hormone is <0.1 mIU/l. The levels of free thyroxine and free triiodothyronine, as a rule, are medium-high value at a subclinical level of thyroid hormone and can help differentiate between endogenous subclinical hyperthyroidism from overt hyperthyroidism. It is recommended to study the thyroid-stimulating hormone level as the first test for the diagnosis of subclinical hyperthyroidism. In identifying low levels of thyroid-stimulating hormone it is necessary to investigate the level of free thyroxine, free or bound triiodothyronine. Patients with primary sub-normal levels of thyroid-stimulating hormone with concentration of thyroid hormones in the upper limit or in normal range should be evaluated within 2-3 months. It is recommended to perform scintigraphy and possible 24-hour test the absorption of radioactive iodine if in patient with 2nd degree endogenous subclinical hyperthyroidism there is nodular goiter to determine treatment strategy. Ultrasonography with color Doppler can be informative for patients with endogenous subclinical hyperthyroidism and nodular goiter. Determining the level of antibodies to thyroid-stimulating hormone receptors can confirm the etiology of autoimmune-induced hyperthyroidism.

Analytic Bias of Thyroid Function Tests: Analysis of a College of American Pathologists Fresh Frozen Serum Pool by 3900 Clinical Laboratories

2005 ◽  
Vol 129 (3) ◽  
pp. 310-317 ◽  
Author(s):  
Bernard W. Steele ◽  
Edward Wang ◽  
George G. Klee ◽  
Linda M. Thienpont ◽  
Steven J. Soldin ◽  
...  
Keyword(s):  
Proficiency Testing ◽  
Matrix Effects ◽  
Thyroid Stimulating Hormone ◽  
Analytic Method ◽  
Free Triiodothyronine ◽  
Analytic Methods ◽  
Clinical Laboratories ◽  
Target Values ◽  
Fresh Frozen ◽  
Stimulating Hormone

Abstract Context.—In proficiency testing surveys, there are differences in the values reported by users of various analytic methods. Two contributors to this variation are calibrator bias and matrix effects of proficiency testing materials. Objectives.—(1) To quantify the biases of the analytic methods used to measure thyroid-stimulating hormone, thyroxine, triiodothyronine, free thyroxine, and free triiodothyronine levels; (2) to determine if these biases are within allowable limits; and (3) to ascertain if proficiency testing materials correctly identify these biases. Design.—A fresh frozen serum specimen was mailed as part of the 2003 College of American Pathologists Ligand and Chemistry surveys. The means and SDs for each analytic method were determined for this sample as well as for a proficiency testing sample from both surveys. In the fresh frozen serum sample, target values for thyroxine and triiodothyronine were determined by isotope dilution/liquid chromatography/tandem mass spectrometry. All other target values in the study were the median of the means obtained for the various analytic methods. Main Outcome Measures.—Calibration biases were calculated by comparing the mean of each analytic method with the appropriate target values. These biases were evaluated against limits based on intra- and interindividual biological variation. Matrix effects of proficiency testing materials were assessed by comparing the rank of highest to lowest analytic method means (Spearman rank test) for each analyte. Participants.—Approximately 3900 clinical laboratories were enrolled in the College of American Pathologists Chemistry and Ligand surveys. Results.—The number of methods in the Ligand Survey that failed to meet the goals for bias was 7 of 17 for thyroid-stimulating hormone and 11 of 13 for free thyroxine. The failure rates were 12 of 16 methods for thyroxine, 8 of 11 for triiodothyronine, and 9 of 11 for free triiodothyronine. The means of the analytic method for the proficiency testing material correlated significantly (P &lt; .05) only with the fresh frozen serum means for thyroxine and thyroid-stimulating hormone in the Chemistry Survey and free triiodothyronine in the Ligand Survey. Conclusions.—A majority of the methods used in thyroid function testing have biases that limit their clinical utility. Traditional proficiency testing materials do not adequately reflect these biases.

Effect of Recombinant Human Erythropoietin (R-Huepo) Therapy on Plasma Ft3, FT4, TSH, FSH, LH, free Testosterone and Prolactin Levels in Hemodialysis Patients

1992 ◽  
Vol 15 (10) ◽  
pp. 585-589 ◽  
Author(s):  
M. Yeksan ◽  
N. Tamer ◽  
M. Cirit ◽  
S. Türk ◽  
G. Akhan ◽  
...  
Keyword(s):  
Free Testosterone ◽  
Hemodialysis Patients ◽  
Thyroid Stimulating Hormone ◽  
Sexual Disorders ◽  
Serum Prolactin ◽  
Control Group ◽  
Dialysis Session ◽  
Free Triiodothyronine ◽  
Human Erythropoietin ◽  
Stimulating Hormone

The aim of this study was to evaluate the effect of r-HuEPO treatment on free triiodothyronine (FT3), free thyroxine (FT4), thyroid stimulating hormone (TSH), follicle-stimulating hormone (FSH), luteinizing hormone (LH), free testosterone and prolactin levels in uremic hemodialysis patients. Twenty-four uremic hemodialysis patients were given r-HuEPO with a dose 60 U/kg as intravenous bolus injection at the end of each dialysis session. Once the hematocrit value of the patient had reached a range of 30-35%, the dose was adjusted so as to keep the hematocrit levels constant. Twenty uremic dialysis patients were taken as control group. The above-mentioned hormone levels of patients and control group were determined before and 4 months after r-HuEPO treatment. After the treatment, serum prolactin levels significantly decreased in both sexes (36.8 ± 7.8 vs 22.9 ± 6.3 ng/ml and 78.3 ±13.3 vs 37.4 ± 10.4 ng/ml male and female, respectively). FT3 and FT4 significantly increased (1.17 vs 1.67 pg/ml, p<0.05, and 0.64 vs 0.084 ng/dl, p<0.05, respectively). TSH levels increased but those changes were not significant. There was no change in the level of any hormone in the control group. Also, the sexual functions of eight male patients treated with r-HuEPO improved and menstruation started again in four female patients. We concluded that r-HuEPO treatment especially decreases prolactin level in uremic hemodialysis patients. It is conceivable that correction of elevated prolactin levels could improve sexual disorders in these patients.

scholarly journals Misleading results from immunoassays of serum free thyroxine in the presence of rheumatoid factor

1997 ◽  
Vol 43 (6) ◽  
pp. 957-962 ◽  
Author(s):  
Anthony G W Norden ◽  
Rodwin A Jackson ◽  
Lorraine E Norden ◽  
A Jane Griffin ◽  
Margaret A Barnes ◽  
...  
Keyword(s):  
Thyroid Hormone ◽  
Rheumatoid Factor ◽  
Equilibrium Dialysis ◽  
Thyroid Stimulating Hormone ◽  
Normal Serum ◽  
Free Thyroxine ◽  
Free Triiodothyronine ◽  
Serum Free ◽  
Serum Free Thyroxine ◽  
Stimulating Hormone

Abstract A novel interference with measurements of serum free thyroxine (FT4) caused by rheumatoid factor (RhF) is described. We found misleading, sometimes gross, increases of FT4 results in 5 clinically euthyroid elderly female patients with high RhF concentrations. All 5 patients had high FT4 on Abbott AxSYM® or IMx® analyzers. “NETRIA” immunoassays gave misleading results in 4 of the 5 patients; Amerlex-MAB® in 2 of 4 patients; AutoDELFIA®in 2 of the 5; and Corning ACS-180® and Bayer Diagnostics Immuno 1® in 1 of the 5. BM-ES700® system results for FT4 in these women remained within the reference range. Results for serum T4, thyroid-stimulating hormone, free triiodothyronine, thyroid-hormone-binding globulin, and FT4 measured by equilibrium dialysis were normal in all 5 patients. Drugs, albumin-binding variants, and anti-thyroid-hormone antibodies were excluded as interferences. Addition to normal serum of the RhF isolated from each of the 5 patients increased the apparent FT4 (Abbott AxSYM). Screening of 83 unselected patients demonstrated a highly significant positive correlation between FT4 (Abbott AxSYM) and RhF concentrations. Discrepant, apparently increased FT4 with a normal result for thyroid-stimulating hormone should lead to measurement of the patient’s RhF concentration.

Laparoscopic ovarian transposition in patients with pelvic cancer

2014 ◽  
Vol 20 (4) ◽  
pp. 207-212
Author(s):  
Kastytis Žilinskas ◽  
Živilė Sabonytė-Balšaitienė ◽  
Narimantas Evaldas Samalavičius
Keyword(s):  
Rectal Cancer ◽  
Ovarian Function ◽  
Vena Cava ◽  
Premenopausal Women ◽  
Tumor Stage ◽  
Reproductive Age ◽  
Stage Iii ◽  
Ovarian Transposition ◽  
Hospitalization Period ◽  
Pelvic Cancer

Background. The aim of this study was to evaluate the feasibility of laparoscopic ovarian transposition prior to radiation therapy on the preservation of hormonal function in the treatment of pelvic cancer. Materials and methods. A chart review of premenopausal women diag­nosed with pelvic cancer, who underwent laparoscopic ovarian transposition to paracolic gutters, then received preoperative radiotherapy at the Center of Oncosurgery, Oncology Institute of Vilnius, from January 2010 to July 2013. Results. A total of 14 patients underwent laparoscopic ovarian transposition. Patients were divided into two groups by localisation of can­cer: 2 (14.29%) patients diagnosed with rectal cancer and 12 (85.71%) with cervical cancer. Patients’ age was from 24 to 42  years with a mean age of 33.71 (SD  ±  5.22) years. The average age of the patients in the first group was 26 (SD ±  2.83) years. In the second group women, aged 29 and 42 years with a mean age of 35 (SD ± 4.35) years, were analyzed. Rectal cancer of stage III was diagnosed in both women of the first group. Tumor stage distribution in the second group, respectively: stage I  –  2  cases (16.67%), stage  II  –  3  cases (25%), stage  III  –  7 cases (58.33%). Seven (58.33%) patients of the second group underwent complete endoscopic staging. In these groups of 14 patients there were 2 (14.3%) complications (injury of the inferior vena cava and postoperative abnormal vaginal bleeding). No postoperative exitus occurred. The mean duration of the operation was 2 hours 26 minutes ± 55 minutes (60–245 minutes), respectively, 2  hours 40  minutes  ±  49  minutes (95–245  minutes) when laparoscopic staging and ovarian transposition was performed and 2  hours 12  minutes  ±  1  hour 1  minute (60–245  minutes) when only ovarian transposition was performed. The hospitalization period ranged from 5 to 52 days (average 12 days). Conclusions. Laparoscopic ovarian transposition is a relatively safe and effective procedure for preserving ovarian function. This procedure should be considered in all reproductive age female patients who need to undergo pelvic irradiation as part of pelvic cancer treatment.

The study of effect of local therapy by essential oils applications on the dynamics of the immune and hormonal indicators and the optimization efficiency of rehabilitation treatment of patients with osteoarthritis

2015 ◽  
Vol 9 (1) ◽  
pp. 0-0
Author(s):  
Бобкова ◽  
A. Bobkova ◽  
Деревнина ◽  
N. Derevnina ◽  
Дашина ◽  
...  
Keyword(s):  
Essential Oils ◽  
Local Therapy ◽  
Thyroid Stimulating Hormone ◽  
Total Testosterone ◽  
Functional Index ◽  
Free Triiodothyronine ◽  
Cytotoxic Cells ◽  
Immunological Status ◽  
Optimization Efficiency ◽  
Stimulating Hormone

Purpose of this research is to study the effects of essential oils applications on the dynamics of the immune and hormonal indicators and clinical picture of osteoarthritis. Materials and methods. 30 women with osteoarthritis were treated by applications of mixture of essential oils: lavender, ginger, peppermint, rosemary, pine, clove, nutmeg, eucalyptus, thyme, anise. The dynamics of the immunological status: the total number of leucocytes; absolute and % of number of total lymphocytes, CD3,CD4+,CD8+, То cells, the indicators of immune-regulatory index CD4+/CD8+, absolute and % indicators CD19, IgG, IgA, IgM was studied. The dynamics of indicators of endocrine systems: somatotropic hormone, prolactin, cortisol, thyroid-stimulating hormone, free thyroxine, free triiodothyronine, paratiritis hormone, calci-tonin, osteocalcin, luteinizing hormone, follicle-stimulating hormone, estradiol and total testosterone, dehydroe-piandrosterone, aldosterone, progesterone, insulin , C-peptide, index HOMA-IR was examined. Results. Before treatment - immunodeficiency CD3, CD4, То cells, increasing CD8 cytotoxic cells, re-ducing the index CD4+ /CD8+ were revealed. After therapy – it was noted increasing CD4, То cells, reducing CD8, increasing the index CD4+ /CD8+. There were a statistically significant increase in testosterone (p&#60;0.05), reduced levels of insulin and glucose (p&#60;0.05), index, HOMA-IR (p&#60;0.05). Against the background of im-provement of immune and hormonal status, the decrease in pain and improvement of function of the joints, according to algo-functional index Lekena (p&#60;0.05), are marked.

scholarly journals Twelve-Month Estrogen Levels in Premenopausal Women With Hormone Receptor–Positive Breast Cancer Receiving Adjuvant Triptorelin Plus Exemestane or Tamoxifen in the Suppression of Ovarian Function Trial (SOFT): The SOFT-EST Substudy

2016 ◽  
Vol 34 (14) ◽  
pp. 1584-1593 ◽  
Author(s):  
Meritxell Bellet ◽  
Kathryn P. Gray ◽  
Prudence A. Francis ◽  
István Láng ◽  
Eva Ciruelos ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Luteinizing Hormone ◽  
Ovarian Function ◽  
Follicle Stimulating Hormone ◽  
Premenopausal Women ◽  
First Year ◽  
Prior Chemotherapy ◽  
Time Points ◽  
Time Point ◽  
Stimulating Hormone

Purpose To describe estradiol (E2), estrone (E1), and estrone sulfate (E1S) levels during the first year of monthly triptorelin plus exemestane or tamoxifen and to assess possible suboptimal suppression while receiving exemestane plus triptorelin. Patients and Methods Premenopausal patients with early breast cancer on the Suppression of Ovarian Function Trial who selected triptorelin as the ovarian suppression method and were randomly assigned to exemestane plus triptorelin or tamoxifen plus triptorelin were enrolled until the target population of 120 patients was reached. Blood sampling time points were 0, 3, 6, 12, 18, 24, 36, and 48 months. Serum estrogens were measured with a highly sensitive and specific assay. This preplanned 12-month analysis evaluated E2, E1, E1S, follicle-stimulating hormone, and luteinizing hormone levels in all patients and the proportion of patients with E2 levels greater than 2.72 pg/mL at any time point during treatment with exemestane plus triptorelin. Results One hundred sixteen patients (exemestane, n = 86; tamoxifen, n = 30; median age, 44 years; median E2, 51 pg/mL; 55% prior chemotherapy) started triptorelin and had one or more samples drawn. With exemestane plus triptorelin, median reductions from baseline E2, E1, and E1S levels were consistently ≥ 95%, resulting in significantly lower levels than with tamoxifen plus triptorelin at all time points. Among patients on exemestane plus triptorelin, 25%, 24%, and 17% had an E2 level greater than 2.72 pg/mL at 3, 6, and 12 months, respectively. Baseline factors related to on-treatment E2 level greater than 2.72 pg/mL were no prior chemotherapy (P = .06), higher body mass index (P = .05), and lower follicle-stimulating hormone and luteinizing hormone (each P < .01). Conclusion During the first year, most patients on exemestane plus triptorelin had E2 levels below the defined threshold of 2.72 pg/mL, consistent with levels reported in postmenopausal patients on aromatase inhibitors, but at each time point, at least 17% of patients had levels greater than the threshold.

Sign in / Sign up

Export Citation Format

Share Document